Catheter Precision, Inc. Announces Issuance of Two Key Patents

About this update from Catheter Precision, Inc.

New Intellectual Property Covers VIVO Technology and Cardionomix Heart Failure Technology FORT MILL, SC, July 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision Inc., (VTAK: NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has received notification of two patents covering separate technologies owned by the company. One patent issued is for European coverage and is patent no. 3742967 entitled "Precise Localization of Cardiac Arrythmia Using Internal Electrocardiography Signals Sensed and Stored by an Implantable Device."  This is the first issuance of IP for the company's endeavor into providing the exact location for ablation of Ventricular Tachycardia (VT) utilizing stored EGM data from an implantable device, such as a pacemaker or cardioverter. This patent joins a list of 18 patents and patent applications covering the VIVO technology. David Jenkins, VTAK's CEO, commented.  "Electrophysiology (EP) is one of the hottest areas in med devices, and our company believes that the ventricular procedures will be the biggest growth area within the entire field of EP. VT is not well treated today.  Often a patient's VT signals are hard to record from the body surface and trying to locate the site of the VT, and where to apply therapy, is very difficult during a procedure.  Our technology provides a GPS-like map to guide the physician to a precise location.  Using internal EGM's is new to the field, and the issuance of this patent protects our interest as we move forward.  We have now completed ten human patients and our technology in this area has early proof of concept. We are extremely pleased with our early results and are excited to be entering a market that is potentially as large as the atrial fibrillation ablation market." The second patent announced today is within the Cardionomix heart failure portfolio of 33 patents and patent applications and is entitled "Systems and Methods for Denoising Physiological Signals during Electrical Neuromodulation".  VTAK owns patented technology for the treatment of Acute Decompensated Heart Failure through the electrical stimulation of the nerve ganglia found in the pulmonary artery.  Stimulation has been found to stabilize the relationship of the autonomic and sym...

View stock analysis, news, and events for Catheter Precision, Inc.